Ongoing Assessments & Recent Research.
Easy access to our work
Alzheimer’s Disease
May 2021Anemia in Chronic Kidney Disease
Feb 2021Atopic Dermatitis
Jul 2021COVID-19
Jul 2020High Cholesterol
Feb 2021Lupus Nephritis
Mar 2021Multiple Myeloma
Apr 2021PTSD: Service Dogs
Nov 2021Unsupported Price Increases
Jan 2021Featured News & Insights.
Learn about our latest work.
ICER Identifies Most Significant 2019 US Drug-Price Hikes — Even After Rebates — That Were Not Supported by New Clinical Evidence
Out of 10 identified drugs that had substantial 2019 price increases on top of already high current spending, seven were not supported by new clinical evidence; the net price increases on these seven drugs alone cost Americans an additional $1.2 billion in annual drug spend.
01/12/2021ICER Publishes Final Evidence Report and Policy Recommendations for Supervised Injection Facilities
Independent appraisal committee determines current evidence is adequate to demonstrate that, compared to syringe exchange programs alone, supervised injection facilities save lives while lowering public health costs. At policy roundtable, experts call on community, state, and federal policy leaders to launch pilot SIF programs in areas of established need and with strong local involvement of […]
01/08/2021ICER Analytics™ Launched to Accelerate the Real-World Application of ICER Reports, Helping Payers, the Life Science Industry, and Health Care Policy Makers Move From Insight to Action
ICER formally launched ICER Analytics™, a new cloud-based platform that will revolutionize the ability of payers, life science companies, patient groups, and others to develop formularies, negotiate drug prices.
11/30/2020The ICER Impact.
New York Medicaid pursued discounts, many of which were in line with ICER reports, which have saved the state over $300 million
Engaged with over 300 patient groups and patient reps
In a landmark international program, HTA agencies around the world can now access ICER’s customizable COVID-19 Cost-Effectiveness Model
Current
Policy Papers.
Easy access to our ongoing policy papers
Unsupported Price Increases
ICER will evaluate selected high-impact drugs with substantial price increases that occurred in 2020. ICER will review changes in the evidence base for each of these drugs and assess whether or not new clinical data exists that could suggest that the drugs could be more beneficial for patients than what was previously understood.
Alternative Policies for Pricing Novel Vaccines and Drug Therapies for COVID-19
This white paper provides a brief overview of approaches to manage the pricing of novel vaccines and treatments in times of public health emergencies.
Cornerstones of ‘Fair’ Drug Coverage
This white paper provides recommendations for appropriate design and implementation of policies that determine patient access to prescription drugs.
Latest
Developments.
Learn more about ICER’s Health Technology Assessment Fellowship! And click here to see our full time job listings.
Learn more about how the patient perspective influences ICER’s work, and learn how you can be involved.
Listen to our podcast, “A Prescription for Fair Pricing“. Subscribe now on Apple, Google, or Spotify.